Stay updated on NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial

Sign up to get notified when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The clinical trial page presents details for a Phase II study of combination treatments for Stage IV non-squamous lung cancer, including eligibility criteria, study arms, outcome measures, locations, and record dates. It also indicates that the study is active but no longer recruiting.
    Difference
    49%
    Check dated 2026-11-08T23:46:00.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The website footer now shows revision v3.8.0 instead of v3.7.2, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T23:46:41.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says that “Super Intelligence” (SI) is replacing “Artificial Intelligence” (AI) in federal agency content.
    Difference
    1%
    Check dated 2026-10-25T23:17:23.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.1 to v3.7.2; the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T23:51:09.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T23:50:01.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, indicating access is blocked. The update adds the 403 page structure and removes the extensive study record content and history sections, leaving an error-focused view instead of the usual study details.
    Difference
    19%
    Check dated 2026-09-20T22:53:24.000Z thumbnail image

Stay in the know with updates to NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NSCLC Carboplatin+Pemetrexed+Bevacizumab+/-Atezolizumab Clinical Trial page.